MARKET

MACK

MACK

Merrimack Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.320
-0.060
-1.37%
Opening 12:43 09/16 EDT
OPEN
4.350
PREV CLOSE
4.380
HIGH
4.350
LOW
4.320
VOLUME
278
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
3.560
MARKET CAP
57.93M
P/E (TTM)
-16.2041
1D
5D
1M
3M
1Y
5Y
A Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) insider increased their holdings by 43% last year
Looking at Merrimack Pharmaceuticals, Inc.'s ( NASDAQ:MACK ) insider transactions over the last year, we can see that...
Simply Wall St. · 09/06 13:50
Western Standard LLC Buys Marlin Business Services Corp, , PFSweb Inc, Sells , Atlantic Power ...
GuruFocus News · 08/18 18:38
Merrimack Pharmaceuticals Q2 EPS $(0.06) Up From $(0.09) YoY
Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly losses of $(0.06) per share. This is a 33.33 percent increase over losses of $(0.09) per share from the same period last year.
Benzinga · 08/05 22:11
Merrimack Pharmaceuticals reports Q2 results
Merrimack Pharmaceuticals (NASDAQ:MACK): Q2 GAAP EPS of -$0.06. As of June 30, 2021, Merrimack had cash and cash equivalents of $14.9M, compared to $14.0M as of December 31, 2020. Press
Seekingalpha · 08/05 21:23
BRIEF-Merrimack Pharmaceuticals Q2 Loss Per Share $0.06
reuters.com · 08/05 20:44
Merrimack Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass., August 05, 2021--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) ("Merrimack" or the "Company") today announced its second quarter 2021 financial results for the period ended June 30, 2021.
Business Wire · 08/05 20:30
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 06/08 09:31
Elevation Oncology Files for $100M IPO
Benzinga · 06/07 18:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MACK. Analyze the recent business situations of Merrimack Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MACK stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 9.15M
% Owned: 68.26%
Shares Outstanding: 13.41M
TypeInstitutionsShares
Increased
7
309.72K
New
5
258.31K
Decreased
17
597.63K
Sold Out
7
31.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.12%
Pharmaceuticals & Medical Research
-0.35%
Key Executives
Chairman/President/Treasurer/Director
Gary Crocker
Independent Director
Eric Andersen
Independent Director
Noah Levy
Independent Director
Ulrik Nielsen
Independent Director
Russell Ray
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.5007
12/13/2019
07/25/2019
Dividend USD 0
09/06/2019
07/25/2019
Special Dividend USD 1.5
09/06/2019
04/04/2017
Dividend USD 0
05/30/2017
04/04/2017
Special Dividend USD 1.055209
05/30/2017
About MACK
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.

Webull offers kinds of Merrimack Pharmaceuticals Inc stock information, including NASDAQ:MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.